Navigation Links
Boehringer Ingelheim's investigational volasertib receives FDA Breakthrough Therapy designation
Date:9/17/2013

is intensive chemotherapy to induce disease remission, followed by consolidation/maintenance chemotherapy. However, many patients over 65 years of age – whose prognosis is typically poor7 – are ineligible for this approach, which involves large doses of chemotherapy over short periods of time,6 and therefore have even fewer treatment options. Volasertib* is currently being investigated in this specific patient population.8

Results from a Phase II study, in newly diagnosed patients with AML considered ineligible for intensive remission induction therapy, demonstrated higher rates of objective response and an improvement in event-free survival in patients receiving volasertib in combination with low-dose cytarabine (LDAC) compared to patients receiving LDAC alone.9 The results were presented at the 54th American Society of Hematology (ASH) annual in December 2012.9

These results led to the initiation in January 2013 of a Phase III trial, POLO-AML-2 (Clinical Trial Identifier: NCT01721876).8 This trial is designed to assess the efficacy and safety of volasertib in combination with LDAC, compared to placebo in combination with LDAC, in patients aged 65 or older with previously untreated AML, ineligible for intensive remission induction therapy.8 The trial is currently enrolling eligible patients.8 For more information please visit ClinicalTrials.gov.8

About Volasertib
Volasertib, an investigational inhibitor of polo-like kinase (Plk), is one of several late-stage compounds that Boehringer Ingelheim is currently evaluating in clinical trials for various solid tumors and hematological cancers. Boehringer Ingelheim is one of the first companies
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
2. Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
3. Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
4. Boehringer Ingelheim Renews and Expands License to NextBio Research Platform
5. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
6. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
7. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
8. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
9. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
10. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
11. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)...  Ascendant Solutions, Inc. (Pink Sheets: ASDS ) ... subsidiary, Dougherty,s Holdings, has acquired Springtown Drug (" ... Springtown, Texas , just north of ... pharmacy has provided retail prescriptions, healthcare products and gifts ... . The Springtown ...
(Date:8/31/2015)... Pa. , Aug. 31, 2015 The ... reversed statewide since Pennsylvania State ... life-saving drug kits, naloxone. Heroin and opioid ... Pennsylvania , killing more individuals than ... approximately 2,400 Pennsylvanians died from a drug overdose. ...
(Date:8/31/2015)... , Aug. 31, 2015 Regen BioPharma, ... development of a novel means of delivering its ... RGBP-248, to liver tumors utilizing a clinically approved ... overcomes previous hurdles with gene silencing therapeutics in ... delivered throughout the whole body.  By utilizing a ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 2Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 3Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3
... June 9 Halozyme Therapeutics,Inc. (Nasdaq: ... products targeting the extracellular matrix, today,announced new ... mellitus program at,the American Diabetes Association,s 68th ... company,s proprietary recombinant human,hyaluronidase enzyme (rHuPH20) with ...
... Pivotal Study Highlighted at Recent Arizona Alzheimer,s ... Consortium Annual Conference in Phoenix -, PHOENIX and ... Health Research Institute today announced that they are,actively enrolling patients ... treatment of Alzheimer,s disease. The study will,evaluate the safety and ...
Cached Medicine Technology:Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 2Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 3Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 4Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 5Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease 2Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease 3
(Date:9/1/2015)... Texas (PRWEB) , ... September ... ... LLC, announced today it has established the MAP Recovery Network, the Premier ... addiction treatment providers. This rapidly-growing alliance is dedicated to the provision of ...
(Date:9/1/2015)... Knoxville, TN (PRWEB) , ... September 01, 2015 ... ... allow users to send information about new patients directly from Practice Perfect to ... and duplicate data entry. , Steven Presement, President of Practice ...
(Date:9/1/2015)... ... 01, 2015 , ... Elizabeth Callahan, MD, founder and medical director of ... to offer RADIESSE® filler treatment for volume loss in the hands. RADIESSE provides an ... in the hands, delivering smooth, natural-looking results that can last up to one year ...
(Date:9/1/2015)... ... September 01, 2015 , ... Routines… every family has them. Whether ... make things easier for parents, caregivers and children too. Here are three reasons why ... and small become more fluid. When a routine is implemented into a child’s schedule, ...
(Date:9/1/2015)... IL (PRWEB) , ... September 01, 2015 , ... ... and Zeel™, has recently sponsored an educational workshop for physician assistants (PAs) practicing ... Injections of Traumeel™ and Zeel™” was held by Dr. Erick Salado, an orthopedic ...
Breaking Medicine News(10 mins):Health News:MAP Health Management Launches the MAP Recovery Network 2Health News:FOTO Announces New Integration Partnership with Practice Perfect 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3Health News:Back into the Swing of Things: How Family Routines Benefit Children 2Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 2Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 3
... of PFOA, PFOS as additives is already being phased ... -- Typical exposures to chemicals that are found ... linked to cancer in animals, may not ... a new report finds. , The two chemicals, perfluorooctanoate ...
... While celebrity DUIs dominate the headlines, a private ... world about the dangers of alcohol misuse and abuse. ... President of Mothers Against Drunk Driving, Mr. Glynn Birch, ... Outreach and Education Services. , , "No ...
... , New research from Washington University in St. Louis has found that students who participated in ... , Click ... , , , ... , , ...
... Mom ,Laps, Up Lowfat Milk to Help Keep Her Muscles ... on the horizon, millions of women have their sights on ... mom Dara Torres, 41, knows there,s more to fitness than ... importance of nutrient-packed lowfat milk to help fuel her fitness ...
... just sit down and relax. Help is on the way. ... Journal ( http://www.fasebj.org ), a team of researchers has ... to go to the bathroom, especially when all other methods ... receptors which, when stimulated, causes the bowels to pass waste, ...
... of radiation combined with chemotherapy improve survival in patients ... study by researchers at the University of Michigan Comprehensive ... lung cancer when the tumor is likely too ... combination of radiation therapy with chemotherapy. But, this new ...
Cached Medicine News:Health News:Common Industrial Chemicals May Not Boost Cancer Risk 2Health News:Common Industrial Chemicals May Not Boost Cancer Risk 3Health News:Innocorp, ltd. Hires Former MADD National President 2Health News:Study finds students with Experience Corps tutors make 60 percent more progress in critical reading skills 2Health News:Study finds students with Experience Corps tutors make 60 percent more progress in critical reading skills 3Health News:Study finds students with Experience Corps tutors make 60 percent more progress in critical reading skills 4Health News:Study finds students with Experience Corps tutors make 60 percent more progress in critical reading skills 5Health News:Study finds students with Experience Corps tutors make 60 percent more progress in critical reading skills 6Health News:Swimmer Dara Torres Sports a White Upper Lip to Praise Milk as Her Post-Exercise Fitness Drink 2Health News:Swimmer Dara Torres Sports a White Upper Lip to Praise Milk as Her Post-Exercise Fitness Drink 3Health News:Swimmer Dara Torres Sports a White Upper Lip to Praise Milk as Her Post-Exercise Fitness Drink 4Health News:Swimmer Dara Torres Sports a White Upper Lip to Praise Milk as Her Post-Exercise Fitness Drink 5Health News:Prune juice not necessary: New research should make bowel movements easier 2Health News:High-dose radiation improves lung cancer survival, U-M study finds 2
... KeraCel Ophthalmic Products are ... formulation of lint-free MEROCEL polyvinyl ... configured to be beneficial to ... being absorbent, and yet firm ...
... Products provide the surgeon ... products for unparalleled fluid ... of fine microsurgical instruments. ... is highly absorbent, fast ...
... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: